Abstract
Objective To examine the timeline from submission of Coronavirus Disease 2019 (COVID)-related original articles compared with non-COVID-related original articles.
Background There have been growing concerns about the speed and rigor of the review process for COVID-related articles by journals.
Methods Using Dimensions, an online searchable platform, we identified PubMed-indexed journals that published >50 COVID-related articles (regardless of article type) between 1/1/2020 and 5/16/2020 and had available data on the date of article receipt. For the control group, we included consecutive full-length original investigations with available receipt date (regardless of topic) published in these journals starting from 3/1/2019 until a 1:2 ratio of COVID to non-COVID-related articles per journal was achieved.
Results The final number included 294 COVID-related full-length original investigations with available article receipt dates published in 16 journals with corresponding 588 control articles from the same journals. The median time from article receipt to online publication was 20 (11-32) days for COVID-articles vs. 119 (62-182) days for controls (P<0.001). The median time to final acceptance (available for 97% of the articles) was 13 (5-23) days for COVID vs. 102 (55-161) days for controls (P<0.001). These observations were seen across all the included journals in the analysis.
Conclusions In this analysis of full-length original investigations published in 16 medical journals, the median time from receipt to final acceptance of COVID-related articles was 8 times faster compared to non-COVID-related articles published in a similar time frame in the previous year. Online publication was 6 times faster for COVID-related articles compared to controls.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study used publicly available data, not related to patients, thus was exempted from IRB
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data are available in the manuscript
